DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

NATIONAL INSTITUTE ON DRUG ABUSE Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Exploiting In Vivo or In Situ Imaging Approaches to Understand HIV-relevant Processes in the Context of Substance Use Disorders (R61/R33 Clinical Trials Optional).

Date: November 12, 2020.

Time: 1:00 PM to 3:00 PM.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-5819
gm145a@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Dated:** October 29, 2020.

Tyeshia M. Roberson, Program Analyst,
Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24396 Filed: 11/3/2020 8:45 am; Publication Date: 11/4/2020]